Paid clinical trial for male and female volunteers with high blood pressure aged 18-65

Receive £3,970 for your time

We invite you to consider taking part in a clinical trial of an investigational drug (ALN-AGT01) being developed for the treatment of high blood pressure.

The main purpose of this clinical trial is to evaluate the safety and tolerability of the investigational drug in adults with high blood pressure. In addition, this clinical trial will evaluate how the body processes the investigational drug and its effect on the body. The information gathered during this clinical trial may be used to support further drug development, including larger trials in patients with high blood pressure.

Study summary

This Phase 1 study will be conducted at our clinical trials unit in London Bridge Newcomen Street. The study has 3 parts: screening, treatment, and follow-up.

Male and female mixed

Register your interest in this clinical trial

 

Screening period: To determine your eligibility for study participation, you would attend a
screening appointment. If you meet the initial eligibility, you will then have an in-house stay
of 14 days (option 1) or 7 days in-house stay with an option of staying 14 days to avoid daily
travel (option 2).
Treatment period: If you are eligible for study participation, then you will have 1 in-house
stay of 3 days / 2 nights. You will receive 1 dose of the study drug.
Follow-Up period: You will be required to be in our unit after receiving the dose of the study
drug as follows:
1 in-house stay of 14 days (option 1) or 7 days in-house stay with an option of staying
14 days to avoid daily travel (option 2), 43 days after receiving the study drug.
8 follow-up visits (every week) over a period of 3 months.
You may be required to attend additional follow-up visits every 84 days, if deemed
necessary by the Research Doctor. During this time, female participants will also be
seen every 30 days to test for pregnancy.

Study dates

Cohort 2a

January 2021
MTWTFSS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
February 2021
MTWTFSS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
March 2021
MTWTFSS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
April 2021
MTWTFSS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
In House Period
Follow Up Appointment

 

Who can take part?

To be eligible to take part in this clinical trial you must:

1. Be 18 and 65 years old.
2. Have been diagnosed with high blood pressure and either:
a. not taking medication for your high blood pressure, or
b. are taking medication for your high blood pressure and have had no changes to the medication in the 30 days prior to screening for this clinical trial.

3. Be a non-smoker
4. Have not used tobacco or nicotine-containing products 6 months prior to receiving the trial drug.
5. Not test positive for hepatitis B/C, HIV, alcohol or drugs or show any evidence of drug or
alcohol abuse.
6. Not be pregnant, breast-feeding, nor planning to become pregnant during the clinical trial.
7. Female volunteers of childbearing potential must agree to the use of highly effective
contraception starting 14 days prior to receiving the trial drug and continuing until trial
completion.

8.Have a Body Mass Index (BMI) between 18.0-35.0 kg/m2, inclusive.

A full list of acceptable contraceptive methods will be discussed in full by a member of the recruitment team and a study doctor during screening.

Study payment

In recognition of the time involved in taking part in this study, you will receive £3970 (£1323 bonus and £2647 study payment)  on completion of the study provided you comply fully with all the study requirements.

Get in touch
Call our team for more information: +44 (0) 20 7042 5800 (opt 1)
We are open weekdays 9am-5pm
or email us: volunteer@richmondpharmacology.com

Ref: C18038_Feb 2019 (email_website_advert text)

The contents of this page have been approved by an ethics committee. Any response to this advertisement will be recorded. Your response will not place you under any obligation to participate in this trial.

You may be required to remain resident in the unit until resolution of any safety issues, after which you will be discharged from the unit.

Register your interest in this clinical trial